Novel RIG-I ligands and methods for producing them

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent discloses novel triphosphate-modified oligonucleotides that act as RIG-I ligands—molecules that can stimulate the innate immune receptor RIG-I. The invention also introduces an efficient method for synthesizing and purifying these modified oligonucleotides at high yield and purity, making them suitable for pharmaceutical applications. The patent describes specific chemical modifications that enhance selectivity for RIG-I, improve chemical stability, and increase immunostimulatory potency, along with detailed strategies for large-scale synthesis and purification, including novel 'capture tag' approaches for efficient separation and purification of the products.

Use CasesContent extracted from patent full text and abstract with AI.

• Development of antiviral and anticancer immunotherapies by stimulating innate immune responses in patients with synthetic RIG-I ligands.
• Design of vaccines or vaccine adjuvants that use RIG-I ligands to boost immune system activation against pathogens or tumor antigens.
• Creation of stable, selective oligonucleotide-based drugs for research or therapeutic use, where enhanced immune stimulation and resistance to degradation are required.
• Improved manufacturing and purification processes for high-purity therapeutic oligonucleotides, leading to scalable pharmaceutical production.
• Further development of molecular biology tools or diagnostics relying on specific immune pathway activation by synthetic RNAs.

BenefitsContent extracted from patent full text and abstract with AI.

• Enables the production of highly selective and stable RIG-I ligands for enhanced and targeted immune activation.
• Provides a scalable, efficient synthesis and purification method, yielding oligonucleotides with pharmaceutical-grade purity suitable for clinical use.
• Allows precise and tunable modification of RNA molecules, improving their stability (e.g., against nucleases) and biological activity.
• Facilitates development of innovative immunotherapies and vaccines with potential for improved patient outcomes in viral infections and cancer.
• Reduces risk of off-target immune activation through rational positioning of chemical modifications to achieve RIG-I specificity, potentially minimizing side effects.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to new triphosphate-modified oligonucleotides which may act as RIG-I ligands as well as a new method allowing the synthesis and purification in high yield and purity suitable for pharmaceutical applications.